Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Barbara Bournet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3679-9454; OpenAlex author ID A5064519018. Sources: OpenAlex.

Their work

Papers
29 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 6 papers · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 29

  1. Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project. Co-author DOI 10.1093/ije/dyag064↗
  2. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  3. Risk Assessment Models for Predicting Venous Thromboembolism in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers17040597↗
  4. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prosp… Co-author DOI 10.1016/j.ebiom.2024.105373↗
  5. Prognostic impact of circulating tumor DNA detection in portal and peripheral blood in resected pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1038/s41598-024-76903-y↗
  6. Early detection of pancreatic cancer by liquid biopsy "PANLIPSY": a french nation-wide study project. Co-author DOI 10.1186/s12885-024-12463-8↗
  7. Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
  8. Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach. Co-author DOI 10.3390/cancers15030761↗
  9. Endoscopic ultrasound as a reliable tool for assessment of pancreatic adenocarcinoma treatment: Example of in situ gene therapy. Co-author DOI 10.1055/a-1799-7774↗
  10. Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component. Co-author DOI 10.15252/emmm.202013502↗
  11. Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2020.102858↗
  12. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. First author DOI 10.1038/s41575-019-0245-4↗
  13. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. First author DOI 10.1053/j.gastro.2019.12.009↗
  14. Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. First author DOI 10.3390/cancers12030618↗
  15. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Co-author DOI 10.3390/cancers12040783↗
  16. Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Tria… Co-author DOI 10.3390/cancers12082028↗
  17. [Venous thromboembolism and pancreatic cancer]. First author DOI 10.1016/j.jdmv.2018.05.003↗
  18. A prospective clinical and biological database for pancreatic adenocarcinoma: the BACAP cohort. Last author DOI 10.1186/s12885-018-4906-4↗
  19. Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes. Co-author DOI 10.3390/ijms18061231↗
  20. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. Co-author DOI 10.1016/j.ejca.2015.11.012↗
  21. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1038/ctg.2016.18↗
  22. First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. First author DOI 10.1038/mt.2015.1↗
  23. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic… Co-author DOI 10.1097/mcg.0000000000000053↗
  24. Salivary MicroRNA in Pancreatic Cancer Patients. Co-author DOI 10.1371/journal.pone.0130996↗
  25. Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i31.10758↗
  26. [Kras oncogene and pancreatic cancer: thirty years after]. Co-author DOI 10.1051/medsci/20132911015↗
  27. KRAS Mutations and Their Correlation With Survival of Patients With Advanced Pancreatic Cancer Co-author DOI 10.1097/mpa.0b013e31826b388b↗
  28. Gene expression signature of advanced pancreatic ductal adenocarcinoma using low density array on endoscopic ultrasound-guided fine needle aspiration samples. Co-author DOI 10.1016/j.pan.2011.12.003↗
  29. Molecular endoscopic ultrasound for diagnosis of pancreatic cancer. Co-author DOI 10.3390/cancers3010872↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Louis Buscail · 22 shared papers, 2011–2026 · strength 2.24
  2. Cindy Canivet · 10 shared papers, 2018–2026 · strength 1.45
  3. Pierre Cordelier · 14 shared papers, 2011–2024 · strength 1.19
  4. Fabrice Muscari · 8 shared papers, 2012–2024 · strength 0.77
  5. Dominique Farge · 5 shared papers, 2018–2025 · strength 0.61
  6. Corinne Frère · 4 shared papers, 2018–2025 · strength 0.55
  7. Charlotte Maulat · 3 shared papers, 2020–2024 · strength 0.50
  8. Bertrand Napoléon · 3 shared papers, 2018–2022 · strength 0.31
  9. Naïma Hanoun · 3 shared papers, 2015–2024 · strength 0.27
  10. Guillaume Le Cosquer · 1 shared paper, 2023 · strength 0.22
  11. Étienne Buscail · 1 shared paper, 2023 · strength 0.22
  12. Eric Assénat · 3 shared papers, 2016–2020 · strength 0.22
  13. Serena Oliveri · 1 shared paper, 2026 · strength 0.21
  14. Lorenzo Gervaso · 1 shared paper, 2026 · strength 0.21
  15. Mireia Obón‐Santacana · 1 shared paper, 2026 · strength 0.21
  16. Lois Riobó‐Mayo · 1 shared paper, 2026 · strength 0.21
  17. Nicola Fazio · 1 shared paper, 2026 · strength 0.21
  18. Victor Rau Moreno · 1 shared paper, 2026 · strength 0.21
  19. Jerome F. Cros · 2 shared papers, 2020–2023 · strength 0.20
  20. Bruno Costa‐Silva · 1 shared paper, 2024 · strength 0.19
  21. Thomas Bardol · 1 shared paper, 2024 · strength 0.19
  22. Catherine Alix‐Panabières · 1 shared paper, 2024 · strength 0.19
  23. Jérôme Torrisani · 4 shared papers, 2011–2015 · strength 0.16
  24. Stéphanie Truant · 2 shared papers, 2018–2020 · strength 0.16
  25. Sylvain Manfrédi · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.